InMed Pharmaceuticals has submitted applications to regulatory authorities in Austria, Israel, and Serbia, seeking clearance to begin clinical testing…
Articles by Marisa Wexler, MS
INM-755, an investigational cannabinol cream for epidermolysis bullosa (EB), showed a positive safety profile and did not interfere…
INM-755, an investigational cannabinol cream for epidermolysis bullosa (EB), showed a good safety profile in a Phase 1 clinical trial…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
The U.S. Food and Drug Administration (FDA) has given rare pediatric disease designation and fast track status…
Filsuvez, a topical formulation being developed by Amryt Pharma, significantly improved wound closure in people with epidermolysis…
The combination of the oral antidepressant mirtazapine with a topical gel containing ketamine and amitriptyline successfully treated…
The topical cream SD-101 failed to improve wound healing in a Phase 3 trial in people with epidermolysis…
A new collaboration between the University Carlos III Madrid (UC3M), Almirall, and the Medina Foundation aims to…
The European Medicines Agency (EMA) granted orphan drug designation to an investigational, and yet unnamed, potential therapy for recessive…
Castle Creek Biosciences has received a $75 million investment to advance its gene therapy program, including FCX-007, a…